Asian Spectator


The Times

.

News Lounge Comes to Türkiye, Fostering Dialogue Across Borders

ANTALYA, TURKEY – Media OutReach Newswire – 14 November 2026 – News Lounge, the flagship program of China News Service, welcomed its first group of international guests since its ov...

Differentiated Cloud Services and Large Deal Momentum Drive In...

BENGALURU, India, April 13, 2022 /PRNewswire-AsiaNet/ -- Strong Revenue growth guidance of 13%-15% and operating margin guidance of 21%-23% for FY23Infosys (NSE: INFY), (BSE: INFY), (NYSE: I...

Latest Nintex K2 Five Enhancements Elevate Rapid Application D...

AUCKLAND, New Zealand, July 30, 2021 /PRNewswire-AsiaNet/ -- -- Newest features include a powerful in-product designer for developing digital forms with no-code custom branding and themes, e...

Higher Logic Opens New Office in Sydney, Australia

SYDNEY, Jan. 29, 2019 /PRNewswire-AsiaNet/-- -- Expansion Will Accelerate International Growth and Increase Investment in Existing Asia Pacific (APAC) CustomersHigher Logic ( https://c212.ne...

Fortune Cup Horse Racing Machine Debuts in Macau

MACAU, Mar 4, 2019 - (ACN Newswire) - Asia Pioneer Entertainment Holdings Limited ("APE" or the "Company", with its subsidiaries collectively referred as the "Group"; Stock Code: 8400.HK) a...

IWUF 4th Taolu World Cup Successfully Wraps Up in Hainan, China

HAIKOU, CHINA - Media OutReach Newswire – 9 July 2026 - The IWUF 4th Taolu World Cup successfully wrapped up in Haikou, Hainan, China, on July 8, 2026. The competition featured 11 men...

Artprice: All Segments of the Art Market are Gold Mines for th...

PARIS, April 15, 2019 /PRNewswire-AsiaNet / -- According to thierry Ehrmann, the found and CEO of Artprice.com, “Our clients, with Artprice, can follow artworks from one appearance at ...

Vinfast Officially Launches Early Booking Program for Three Battery-Swapping E-Motorcycle Models in Indonesia

JAKARTA, INDONESIA - Media OutReach Newswire - 20 May 2026 - VinFast has officially launched the Early Booking Program for three battery-swapping e-motorcycle models in Indonesia, including...

Son Heung-Min teams up with Tiger Beer to encourage everyone to pursue their boldest ambitions in the Year of the Tiger

Son leads global movement to encourage fans to “Uncage Your Tiger” in 2022.SINGAPORE - Media OutReach - 4 January 2022 - Tiger Beer, the number one international p...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalmarsbahisuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet resmi girişStreamEastStreamEastjojobet